tabelecleucel

Overview

Tabelecleucel is an allogeneic EBV-specific cytotoxic T lymphocyte (CTL) cell therapy. It was evaluated in EBV-positive recurrent/metastatic nasopharyngeal carcinoma (NPC), but development in NPC has been terminated.

Evidence in the corpus

• Tabelecleucel (allogeneic EBV-CTL) in EBV+ R/M NPC (NCT03769467, n=12): stable disease in 50%, no objective responses; development in NPC has been terminated due to lack of objective responses PMID:24952746.

Resistance mechanisms

Cancer types (linked)

• NPC

Sources

This page was processed by entity-page-writer on 2026-05-11.